IO Biotech completes enrollment in Phase 3 trial of advanced melanoma

IO Biotech (IOBT) announced that it has completed enrollment in the pivotal Phase 3 clinical trial for IO102-IO103, in combination with KEYTRUDA, Merck’s (MRK) anti-PD-1 therapy, in patients with advanced melanoma. As of today, 380 patients have been randomized in the trial. “The Phase 1/2 data of IO102-IO103 in combination with a PD-1 inhibitor in patients with first-line advanced melanoma demonstrated approximately double the effect than would have been expected with PD-1 inhibitor monotherapy in this patient population – with 80% of patients achieving a response, 50% of patients achieving a complete response, and no additional systemic toxicity than that typically seen with a PD-1 inhibitor alone,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “Completion of enrollment in this pivotal Phase 3 trial marks a significant milestone for our company and is a testament to the enthusiasm for this study among our investigators and the patient community. We would like to extend our gratitude to the patients, caregivers, investigators, and study staff whose commitment to this trial is helping bring us closer to potentially changing the treatment paradigm for patients with advanced melanoma.”